
According to the available scientific evidence, the best alternative to the use of crystalline insulin in the treatment of hypercalcemia is the ultra–short-acting insulin lispro; since it provides the greatest amount of information regarding its efficacy (which shows no significant differences compared to crystalline insulin), its safety profile has been studied, and it is considered safer for patients with renal impairment.
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
